8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
May 6, 2026·SEC
The Beauty Health Company(SKIN)Earnings, Financials & Key Ratios
SKIN•NASDAQ
Price updated Jun 19, 2026
SectorConsumer DefensiveIndustryHousehold ProductsSub-IndustrySuppliers, Durables and Specialty Retailers
AboutThe Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.Show more
- Revenue$301M-10.0%
- EBITDA$5M+111.9%
- Net Income-$10M+67.3%
- EPS (Diluted)-0.16+55.6%
- Gross Margin65.28%+19.7%
- EBITDA Margin1.51%+113.2%
- Operating Margin-6.92%+65.9%
- Net Margin-3.16%+63.6%
- ROE-16.86%+67.8%
SKIN Key Insights
The Beauty Health Company (SKIN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 20.1%
- ✓Strong Piotroski F-Score: 7/9
- ✓Strong 5Y sales CAGR of 20.4%
- ✓Share count reduced 4.7% through buybacks
- ✓Trading at only 1.5x book value
✗Weaknesses
- ✗High debt to equity ratio of 6.2x
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SKIN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SKIN Price & Volume
The Beauty Health Company (SKIN) stock price & volume — 10-year historical chart
Loading chart...
SKIN Growth Metrics
The Beauty Health Company (SKIN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years20.36%
3 Years-6.32%
TTM-8.17%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM84.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM57.96%
Return on Capital
10 Years-5.62%
5 Years-7.48%
3 Years-9.65%
Last Year-4.47%
SKIN Recent Earnings
The Beauty Health Company (SKIN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.05+44.4%
$0.09
Rev
$65M-2.1%
$66M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.06+14.3%
$0.07
Rev
$82M+5.4%
$78M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.09-12.5%
$0.08
Rev
$71M-9.5%
$78M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.03+150.0%
$0.06
Rev
$78M+14.4%
$68M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.05vs $0.09+44.4% | $65Mvs $66M-2.1% |
| Q2 2026 | Mar 12, 2026 | $0.06vs $0.07+14.3% | $82Mvs $78M+5.4% |
| Q4 2025 | Nov 6, 2025 | $0.09vs $0.08-12.5% | $71Mvs $78M-9.5% |
| Q3 2025 | Aug 7, 2025 | $0.03vs $0.06+150.0% | $78Mvs $68M+14.4% |
Based on last 12 quarters of dataView full earnings history →
SKIN Peer Comparison
The Beauty Health Company (SKIN) competitors in Suppliers, Durables and Specialty Retailers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ELF | 3.82B | 64.20 | 145.91 | 24.59% | 3.34% | 5.16% | 0.81 | |
 IPAR | 3.17B | 99.09 | 18.91 | 2.49% | 13.46% | 18.37% | 0.20 | |
 COTY | 1.72B | 1.95 | -4.43 | -3.68% | -9.26% | -14.13% | 1.07 | |
 NUS | 243.72M | 5.02 | 1.58 | -14.26% | 3.78% | 6.84% | 0.45 | |
 USNA | 348.47M | 18.88 | 32.55 | 8.28% | 1.16% | 1.84% | 0.02 | |
 ESTA | 2.49B | 84.81 | -49.31 | 27.14% | -19.05% | -225.86% | 11.23 | |
 INMD | 849.01M | 13.40 | 9.37 | -6.16% | 23.27% | 13.28% | 0.02 | |
 SSKN | 806.68K | 0.14 | -0.10 | -8.54% | -21.13% | -360.33% | 5.59 |
Compare SKIN vs Peers
The Beauty Health Company (SKIN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SKIN Income Statement
The Beauty Health Company (SKIN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 166.62M | 119.09M | 260.09M | 365.88M | 397.99M | 334.29M | 300.79M | 296.11M |
Revenue Growth % | - | -28.53% | 118.39% | 40.67% | 8.78% | -16% | -10.02% | -8.17% |
Cost of Goods Sold | 60.11M | 51.89M | 81.55M | 117.1M | 242.88M | 152M | 104.43M | 103.93M |
COGS % of Revenue | 36.08% | 43.57% | 31.35% | 32% | 61.03% | 45.47% | 34.72% | - |
Gross Profit | 106.51M▲ 0% | 67.2M▼ 36.9% | 178.54M▲ 165.7% | 248.78M▲ 39.3% | 155.11M▼ 37.7% | 182.3M▲ 17.5% | 196.36M▲ 7.7% | 192.18M▲ 0% |
Gross Margin % | 63.92% | 56.43% | 68.65% | 68% | 38.97% | 54.53% | 65.28% | 64.9% |
Gross Profit Growth % | - | -36.91% | 165.69% | 39.34% | -37.65% | 17.52% | 7.72% | - |
Operating Expenses | 93.05M | 84.38M | 218.47M | 274.62M | 286.03M | 250.07M | 217.17M | 202.76M |
OpEx % of Revenue | 55.84% | 70.85% | 84% | 75.06% | 71.87% | 74.81% | 72.2% | - |
Selling, General & Admin | 88.44M | 80.97M | 210.27M | 266.18M | 275.93M | 243.77M | 211.54M | 197.03M |
SG&A % of Revenue | 53.08% | 67.99% | 80.85% | 72.75% | 69.33% | 72.92% | 70.33% | - |
Research & Development | 4.61M | 3.41M | 8.2M | 8.44M | 10.1M | 6.3M | 5.63M | 5.73M |
R&D % of Revenue | 2.77% | 2.86% | 3.15% | 2.31% | 2.54% | 1.88% | 1.87% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | 13.46M▲ 0% | -17.18M▼ 227.6% | -39.93M▼ 132.4% | -25.84M▲ 35.3% | -130.92M▼ 406.6% | -67.77M▲ 48.2% | -20.8M▲ 69.3% | -10.58M▲ 0% |
Operating Margin % | 8.08% | -14.43% | -15.35% | -7.06% | -32.89% | -20.27% | -6.92% | -3.57% |
Operating Income Growth % | - | -227.63% | -132.38% | 35.28% | -406.63% | 48.23% | 69.31% | - |
EBITDA | 27.2M | -2.78M | -22M | -2.97M | -96.24M | -38.3M | 4.55M | 13.94M |
EBITDA Margin % | 16.32% | -2.34% | -8.46% | -0.81% | -24.18% | -11.46% | 1.51% | 4.71% |
EBITDA Growth % | - | -110.22% | -691.01% | 86.51% | -3142.65% | 60.21% | 111.87% | 144.1% |
D&A (Non-Cash Add-back) | 13.74M | 14.4M | 17.93M | 22.87M | 34.67M | 29.48M | 25.35M | 24.52M |
EBIT | 14.16M | -17.21M | -368.86M | 58.73M | -88.24M | -19.14M | 13.39M | 18.29M |
Net Interest Income | -17.09M | -21.27M | -11.74M | -4.22M | 9.52M | 6.23M | -10.37M | -15.76M |
Interest Income | 0 | 0 | 39K | 9.18M | 23.17M | 16.64M | 8.95M | 7.41M |
Interest Expense | 17.09M | 21.27M | 11.78M | 13.39M | 13.65M | 10.41M | 19.33M | 23.17M |
Other Income/Expense | -16.4M | -21.3M | -340.71M | 71.18M | 29.03M | 38.22M | 14.87M | 7.05M |
Pretax Income | -2.94M▲ 0% | -38.48M▼ 1211.2% | -380.64M▼ 889.1% | 45.34M▲ 111.9% | -101.89M▼ 324.7% | -29.55M▲ 71.0% | -5.94M▲ 79.9% | -3.53M▲ 0% |
Pretax Margin % | -1.76% | -32.31% | -146.35% | 12.39% | -25.6% | -8.84% | -1.97% | -1.19% |
Income Tax | -1.3M | -9.31M | -1.88M | 1.11M | -1.77M | -452K | 3.58M | 2.49M |
Effective Tax Rate % | 44.19% | 24.19% | 0.49% | 2.46% | 1.74% | 1.53% | -60.31% | -70.43% |
Net Income | -1.64M▲ 0% | -29.18M▼ 1681.1% | -378.76M▼ 1198.2% | 44.22M▲ 111.7% | -100.12M▼ 326.4% | -29.1M▲ 70.9% | -9.52M▲ 67.3% | -6.02M▲ 0% |
Net Margin % | -0.98% | -24.5% | -145.63% | 12.09% | -25.16% | -8.7% | -3.16% | -2.03% |
Net Income Growth % | - | -1681.14% | -1198.25% | 111.68% | -326.38% | 70.94% | 67.29% | 84.36% |
Net Income (Continuing) | -1.64M | -29.18M | -378.76M | 44.22M | -100.12M | -29.1M | -9.52M | -6.02M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.05▲ 0% | -0.85▼ 1566.7% | -3.67▼ 331.8% | -0.23▲ 93.7% | -0.76▼ 230.4% | -0.36▲ 52.6% | -0.16▲ 55.6% | -0.05▲ 0% |
EPS Growth % | - | -1566.67% | -331.76% | 93.73% | -230.43% | 52.63% | 55.56% | 57.96% |
EPS (Basic) | -0.05 | -0.85 | -3.67 | 0.30 | -0.76 | -0.23 | -0.08 | - |
Diluted Shares Outstanding | 32.14M | 34.29M | 102.11M | 148.51M | 131.68M | 142.49M | 135.8M | 131.4M |
Basic Shares Outstanding | 32.14M | 34.29M | 102.11M | 147.55M | 131.68M | 123.83M | 126.38M | 127.79M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
SKIN Balance Sheet
The Beauty Health Company (SKIN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 54.17M | 59.09M | 1B | 783.27M | 698.25M | 477.12M | 309.5M | 277.7M |
Cash & Short-Term Investments | 7.31M | 9.49M | 901.89M | 568.2M | 523.02M | 370.06M | 232.7M | 204.4M |
Cash Only | 7.31M | 9.49M | 901.89M | 568.2M | 523.02M | 370.06M | 232.7M | 204.4M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 23.72M | 23.19M | 51.42M | 77.77M | 55.03M | 28.46M | 23.44M | 20.25M |
Days Sales Outstanding | 51.96 | 71.06 | 72.17 | 77.59 | 50.47 | 31.08 | 28.44 | 29.65 |
Inventory | 19.43M | 23.2M | 35.26M | 109.66M | 91.32M | 69.11M | 48M | 47.7M |
Days Inventory Outstanding | 118.01 | 163.2 | 157.82 | 341.81 | 137.24 | 165.96 | 167.77 | 185.29 |
Other Current Assets | 0 | 2.58M | 0 | 27.65M | 28.88M | 9.49M | 5.36M | 5.35M |
Total Non-Current Assets | 172.18M | 163.74M | 217.91M | 219.81M | 230.86M | 208.56M | 190.3M | 195.5M |
Property, Plant & Equipment | 10.8M | 9.19M | 31.18M | 33.82M | 26.35M | 19.57M | 14.1M | 22.6M |
Fixed Asset Turnover | 15.43x | 12.96x | 8.34x | 10.82x | 15.11x | 17.08x | 21.33x | 17.26x |
Goodwill | 98.52M | 98.53M | 123.69M | 124.59M | 125.82M | 123.5M | 126.6M | 126.2M |
Intangible Assets | 60.29M | 50.94M | 56.01M | 46.39M | 62.12M | 47.51M | 35.8M | 32.8M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2.34M | 4.81M | 6.71M | 14.19M | 16.04M | 14.09M | 11.9M | 11.5M |
Total Assets | 226.35M▲ 0% | 222.84M▼ 1.6% | 1.22B▲ 447.0% | 1B▼ 17.7% | 929.11M▼ 7.4% | 685.68M▼ 26.2% | 499.8M▼ 27.1% | 473.2M▲ 0% |
Asset Turnover | 0.74x | 0.53x | 0.21x | 0.36x | 0.43x | 0.49x | 0.60x | 0.60x |
Asset Growth % | - | -1.55% | 446.95% | -17.7% | -7.37% | -26.2% | -27.11% | -113.58% |
Total Current Liabilities | 37.82M | 30.93M | 76.44M | 71.71M | 115.01M | 68.15M | 186.3M | 155.2M |
Accounts Payable | 14.26M | 18.48M | 29.05M | 28.47M | 44.77M | 21.94M | 15.6M | 15.9M |
Days Payables Outstanding | 86.57 | 130.02 | 130.02 | 88.73 | 67.28 | 52.69 | 54.53 | 63.02 |
Short-Term Debt | 8.93M | 512K | 0 | 0 | 0 | 0 | 129.09M | 107.1M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 450K | 2.38M | 0 | 706K |
Other Current Liabilities | 0 | 2.46M | 18.28M | 5.64M | 25.01M | 2.14M | 40.36M | 31.75M |
Current Ratio | 1.43x | 1.91x | 13.09x | 10.92x | 6.07x | 7.00x | 1.66x | 1.79x |
Quick Ratio | 0.92x | 1.16x | 12.63x | 9.39x | 5.28x | 5.99x | 1.40x | 1.48x |
Cash Conversion Cycle | 83.4 | 104.24 | 99.97 | 330.66 | 120.43 | 144.35 | 141.69 | 151.92 |
Total Non-Current Liabilities | 189.74M | 221.87M | 840.07M | 764.32M | 754.72M | 565.73M | 252.47M | 262.79M |
Long-Term Debt | 180.85M | 216.02M | 729.91M | 734.14M | 738.37M | 552.2M | 240.43M | 241.28M |
Capital Lease Obligations | 276K | 0 | 12.78M | 12.69M | 9.32M | 10.81M | 9.24M | 47.01M |
Deferred Tax Liabilities | 8.29M | 3.99M | 3.56M | 2.01M | 702K | 396K | 393K | 1.11M |
Other Non-Current Liabilities | 325K | 1.85M | 93.82M | 15.47M | 6.32M | 2.32M | 2.41M | 2.37M |
Total Liabilities | 227.56M | 252.79M | 916.51M | 836.03M | 869.72M | 633.88M | 438.7M | 418M |
Total Debt | 190.2M | 216.54M | 746.41M | 751.79M | 752.29M | 568.16M | 378.7M | 367.2M |
Net Debt | 182.89M | 207.05M | -155.48M | 183.59M | 229.26M | 198.09M | 146M | 162.8M |
Debt / Equity | - | - | 2.47x | 4.50x | 12.67x | 10.97x | 6.20x | 6.65x |
Debt / EBITDA | 6.99x | - | - | - | - | - | 83.30x | 26.34x |
Net Debt / EBITDA | 6.72x | - | - | - | - | - | 32.12x | 11.68x |
Interest Coverage | 0.83x | -0.81x | -31.32x | 4.39x | -6.46x | -1.84x | 0.69x | 0.79x |
Total Equity | -1.21M▲ 0% | -29.96M▼ 2380.1% | 302.3M▲ 1109.0% | 167.05M▼ 44.7% | 59.39M▼ 64.4% | 51.8M▼ 12.8% | 61.1M▲ 17.9% | 55.2M▲ 0% |
Equity Growth % | - | -2380.13% | 1109% | -44.74% | -64.45% | -12.77% | 17.95% | 54.68% |
Book Value per Share | -0.04 | -0.87 | 2.96 | 1.12 | 0.45 | 0.36 | 0.45 | 0.42 |
Total Shareholders' Equity | -1.21M | -29.96M | 302.3M | 167.05M | 59.39M | 51.8M | 61.1M | 55.2M |
Common Stock | 0 | 4K | 16K | 14K | 12K | 12K | 13K | 13K |
Retained Earnings | -14.43M | -43.6M | -418.71M | -378.75M | -478.87M | -507.96M | -517.5M | -524.1M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 28K | 242K | -1.26M | -4.53M | -3.04M | -6.95M | -1.4M | -1.7M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SKIN Cash Flow Statement
The Beauty Health Company (SKIN) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.73M | -12.44M | -28.36M | -106.6M | 21.75M | 16.13M | 37.5M | 28.93M |
Operating CF Margin % | 1.04% | -10.44% | -10.9% | -29.14% | 5.46% | 4.83% | 12.47% | - |
Operating CF Growth % | - | -819.68% | -128.06% | -275.87% | 120.4% | -25.82% | 132.43% | -244.05% |
Net Income | -1.64M | -29.18M | -375.11M | 44.38M | -100.12M | -29.1M | -9.5M | -6.02M |
Depreciation & Amortization | 13.88M | 14.4M | 21.14M | 22.02M | 34.67M | 33.68M | 0 | 17.6M |
Stock-Based Compensation | 103K | 363K | 12.42M | 28.5M | 22.54M | 26.7M | 0 | 11.35M |
Deferred Taxes | -4.65M | -4.34M | -3.76M | -1.79M | 0 | -3.75M | 0 | 409K |
Other Non-Cash Items | 1.94M | 8.9M | 335.62M | -59.42M | 41.29M | 16M | 36.63M | 9.9M |
Working Capital Changes | -7.91M | -2.58M | -18.66M | -140.28M | 23.36M | -27.39M | 10.37M | -4.29M |
Change in Receivables | -11.05M | 3.7M | -31.01M | -32.02M | 12.85M | 20.8M | 8.59M | 3.67M |
Change in Inventory | -4.77M | -3.21M | -9.44M | -82.1M | 19.57M | -10.5M | 15.8M | 11.89M |
Change in Payables | 4.31M | 4.89M | 10.52M | 1.61M | 15.78M | -43.78M | -7.2M | -13.59M |
Cash from Investing | -12.48M | -3.82M | -37.73M | -18.87M | -31.51M | -6.79M | -5.16M | -5.67M |
Capital Expenditures | -10.42M | -3.82M | -15.62M | -17.39M | -13.05M | -6.79M | -5.16M | -121K |
CapEx % of Revenue | 6.25% | 3.21% | 6% | 4.75% | 3.28% | 2.03% | 1.72% | 0.04% |
Acquisitions | -2.06M | 0 | -22.9M | -1.48M | -18.46M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 781K | 0 | 0 | 0 | 0 | -5.55M |
Cash from Financing | 14.58M | 18.27M | 959.03M | -205.24M | -37.45M | -158.34M | -174.9M | -195.58M |
Debt Issued (Net) | 16.5M | 19.73M | 524.51M | 0 | 0 | -156.08M | -173.35M | -431.82M |
Equity Issued (Net) | 0 | -154K | 938.38M | -160M | -35.63M | -1.96M | -1.57M | -895K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -154K | 0 | -160M | -32.4M | -1.96M | 0 | -895K |
Other Financing | -1.92M | -1.3M | -503.86M | -45.24M | -1.82M | -302K | 26K | 237.14M |
Net Change in Cash | 3.73M▲ 0% | 2.18M▼ 41.6% | 892.4M▲ 40854.6% | -333.69M▼ 137.4% | -45.17M▲ 86.5% | -152.96M▼ 238.6% | -137.4M▲ 10.2% | -168.66M▲ 0% |
Free Cash Flow | -8.69M▲ 0% | -16.25M▼ 86.9% | -43.98M▼ 170.6% | -123.99M▼ 182.0% | 8.7M▲ 107.0% | 9.34M▲ 7.3% | 37.18M▲ 298.1% | 28.45M▲ 0% |
FCF Margin % | -5.22% | -13.65% | -16.91% | -33.89% | 2.19% | 2.79% | 12.36% | 9.61% |
FCF Growth % | - | -86.94% | -170.58% | -181.95% | 107.02% | 7.34% | 298.09% | -4.69% |
FCF per Share | -0.27 | -0.47 | -0.43 | -0.83 | 0.07 | 0.07 | 0.27 | 0.22 |
FCF Conversion (FCF/Net Income) | -1.05x | 0.43x | 0.07x | -2.41x | -0.22x | -0.55x | -3.94x | -4.72x |
Interest Paid | 15.73M | 13.54M | 10.25M | 0 | 9.38M | 8.01M | 0 | 0 |
Taxes Paid | 861K | 2.43M | 1.7M | 0 | 2.27M | 2.8M | 0 | 0 |
SKIN Key Ratios
The Beauty Health Company (SKIN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -278.16% | 18.84% | -88.42% | -52.34% | -16.86% | -9.41% |
Return on Invested Capital (ROIC) | -7.18% | -18.49% | -7.79% | -30.72% | -18.88% | -6.83% | -3.57% |
Gross Margin | 56.43% | 68.65% | 68% | 38.97% | 54.53% | 65.28% | 64.9% |
Net Margin | -24.5% | -145.63% | 12.09% | -25.16% | -8.7% | -3.16% | -2.03% |
Debt / Equity | - | 2.47x | 4.50x | 12.67x | 10.97x | 6.20x | 6.65x |
Interest Coverage | -0.81x | -31.32x | 4.39x | -6.46x | -1.84x | 0.69x | 0.79x |
FCF Conversion | 0.43x | 0.07x | -2.41x | -0.22x | -0.55x | -3.94x | -4.72x |
Revenue Growth | -28.53% | 118.39% | 40.67% | 8.78% | -16% | -10.02% | -8.17% |
Related:SKIN Dividend History·SKIN Revenue History·SKIN Price History·SKIN P/E History·SKIN Financial Ratios·SKIN Institutional Holders
SKIN SEC Filings & Documents
The Beauty Health Company (SKIN) SEC filings — annual & quarterly reports (10-K, 10-Q)
SKIN Frequently Asked Questions
The Beauty Health Company (SKIN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
The Beauty Health Company (SKIN) reported $296.1M in revenue for fiscal year 2025. This represents a 78% increase from $166.6M in 2019.
The Beauty Health Company (SKIN) saw revenue decline by 10.0% over the past year.
The Beauty Health Company (SKIN) reported a net loss of $6.0M for fiscal year 2025.
Dividend & Returns
The Beauty Health Company (SKIN) has a return on equity (ROE) of -16.9%. Negative ROE indicates the company is unprofitable.
The Beauty Health Company (SKIN) generated $28.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.